GLP1R and hydrops fetalis: In patients with ASCVD and HF, subgroup analyses of previous RCTs suggest that both GLP-1 RA and SGLT2i may offer potential benefits compared to placebo.11–17 However, these trials included relatively small subgroups of patients with both ASCVD and HF, and these outcomes were not the primary focus of the studies.